Comparing of Lexicon Pharmaceuticals Inc. (LXRX) and Abeona Therapeutics Inc. (NASDAQ:ABEO)

Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) and Abeona Therapeutics Inc. (NASDAQ:ABEO) compete against each other in the Biotechnology sector. We will compare them and contrast their analyst recommendations, institutional ownership, profitability, risk, dividends, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Lexicon Pharmaceuticals Inc. 47.05M 12.76 100.53M -0.95 0.00
Abeona Therapeutics Inc. 2.47M 103.03 64.70M -1.19 0.00

Table 1 shows top-line revenue, earnings per share (EPS) and valuation of the two companies.


Table 2 demonstrates the return on assets, return on equity and net margins of Lexicon Pharmaceuticals Inc. and Abeona Therapeutics Inc.

Net Margins Return on Equity Return on Assets
Lexicon Pharmaceuticals Inc. -213.67% 376.4% -33.8%
Abeona Therapeutics Inc. -2,619.43% 0% 0%

Volatility and Risk

A 0.63 beta indicates that Lexicon Pharmaceuticals Inc. is 37.00% less volatile compared to Standard and Poor’s 500. Abeona Therapeutics Inc. has a 1.9 beta and it is 90.00% more volatile than Standard and Poor’s 500.


The current Quick Ratio of Lexicon Pharmaceuticals Inc. is 5 while its Current Ratio is 5.2. Meanwhile, Abeona Therapeutics Inc. has a Current Ratio of 3.3 while its Quick Ratio is 3.3. Lexicon Pharmaceuticals Inc. is better positioned to pay off its short-term and long-term debts than Abeona Therapeutics Inc.

Analyst Recommendations

The following table shown below contains the ratings and recommendations for Lexicon Pharmaceuticals Inc. and Abeona Therapeutics Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Lexicon Pharmaceuticals Inc. 0 0 2 3.00
Abeona Therapeutics Inc. 0 0 5 3.00

Lexicon Pharmaceuticals Inc.’s upside potential currently stands at 195.04% and an $16.67 consensus price target. Abeona Therapeutics Inc. on the other hand boasts of a $25 consensus price target and a 383.56% potential upside. Based on the results shown earlier, Abeona Therapeutics Inc. is looking more favorable than Lexicon Pharmaceuticals Inc., analysts belief.

Institutional and Insider Ownership

The shares of both Lexicon Pharmaceuticals Inc. and Abeona Therapeutics Inc. are owned by institutional investors at 0% and 68.3% respectively. Insiders owned 0.3% of Lexicon Pharmaceuticals Inc. shares. Comparatively, 0.3% are Abeona Therapeutics Inc.’s share owned by insiders.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Lexicon Pharmaceuticals Inc. -9.14% 8.94% 26.17% -28.93% -31.93% -2.71%
Abeona Therapeutics Inc. -7.5% -5.21% 10.47% -22.22% -65.17% 1.96%

For the past year Lexicon Pharmaceuticals Inc. has -2.71% weaker performance while Abeona Therapeutics Inc. has 1.96% stronger performance.


Lexicon Pharmaceuticals Inc. beats on 6 of the 11 factors Abeona Therapeutics Inc.

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with SSA therapy in adults. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that is in Phase 3 clinical trials for use in the treatment of type 1 and type 2 diabetes; LX2761, which is in Phase 1 development for use in the treatment of diabetes; and LX9211 for use as a treatment for neuropathic pain. The company has license and collaboration agreements with Sanofi; Ipsen Pharma SAS; Bristol-Myers Squibb Company; and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. The companyÂ’s lead programs are ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B; and ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A. It is also developing EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); EB-201 for for epidermolysis bullosa (EB); ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; ABO-301, an AAV-based gene therapy for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. In addition, the company is developing plasma-based protein therapy pipeline, including SDF Alpha, an alpha-1 protease inhibitor for inherited COPD using its proprietary salt diafiltration ethanol-free process. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.